Last reviewed 2026-04-23 · How we verify

HS628+MTX

HS628 is a small-molecule inhibitor combined with methotrexate (MTX) to target immune-mediated inflammatory conditions through dual pathway suppression.

HS628 is a small-molecule inhibitor combined with methotrexate (MTX) to target immune-mediated inflammatory conditions through dual pathway suppression. Used for Rheumatoid arthritis or other autoimmune inflammatory conditions (specific indication not publicly confirmed).

At a glance

Mechanism of action

HS628 is a selective inhibitor of a key immune signaling pathway, likely targeting JAK or similar kinase involved in inflammatory cytokine signaling. When combined with methotrexate, a classical immunosuppressive and antiproliferative agent, the combination aims to provide synergistic suppression of pathogenic immune responses. This dual-mechanism approach is typical for treating autoimmune and inflammatory diseases.

Approved indications

• Rheumatoid arthritis or other autoimmune inflammatory conditions (specific indication not publicly confirmed)

Common side effects

• Infection (including serious infections)
• Hematologic abnormalities
• Hepatotoxicity
• Gastrointestinal disturbance

Key clinical trials

• Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HS628+MTX CI brief — competitive landscape report
• HS628+MTX updates RSS · CI watch RSS
• Zhejiang Hisun Pharmaceutical Co. Ltd. portfolio CI